• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.

作者信息

DeKlotz Cynthia M C, Ogram Alicia E, Singh Saurabh, Dronavalli Sridhar, MacGregor Jennifer L

出版信息

Arch Dermatol. 2011 Sep;147(9):1116-7. doi: 10.1001/archdermatol.2011.254.

DOI:10.1001/archdermatol.2011.254
PMID:21931059
Abstract
摘要

相似文献

1
Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.外用雷帕霉素治疗结节性硬化症面部血管纤维瘤疗效显著：优化治疗方案
Arch Dermatol. 2011 Sep;147(9):1116-7. doi: 10.1001/archdermatol.2011.254.
2
Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.外用雷帕霉素：治疗结节性硬化症面部血管纤维瘤的新方法。
Arch Dermatol. 2010 Jul;146(7):715-8. doi: 10.1001/archdermatol.2010.125.
3
[Topical sirolimus 0.4% formulation for treatment of facial angiofibromas].[用于治疗面部血管纤维瘤的0.4%西罗莫司局部制剂]
Farm Hosp. 2012 Sep-Oct;36(5):433-4. doi: 10.1016/j.farma.2011.09.006. Epub 2012 Jul 31.
4
[Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].[外用西罗莫司治疗与结节性硬化症相关的面部血管纤维瘤]
Ugeskr Laeger. 2013 Oct 21;175(43):2569-70.
5
A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.一种用于治疗结节性硬化症面部血管纤维瘤的新型外用雷帕霉素乳膏。
J Child Neurol. 2013 Jul;28(7):933-6. doi: 10.1177/0883073813488664. Epub 2013 May 16.
6
Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.外用0.2%雷帕霉素治疗结节性硬化症的面部血管纤维瘤和色素减退斑。
Actas Dermosifiliogr. 2014 Oct;105(8):802-3. doi: 10.1016/j.ad.2013.09.013. Epub 2013 Dec 17.
7
Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.两名结节性硬化症患者局部应用口服雷帕霉素溶液（1mg/mL）治疗面部血管纤维瘤。
Br J Dermatol. 2011 Oct;165(4):922-3. doi: 10.1111/j.1365-2133.2011.10476.x.
8
Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.成人与结节性硬化症伴发的青少年血管纤维瘤患者中局部使用 0.2%西罗莫司的疗效比较。
Dermatology. 2018;234(1-2):13-22. doi: 10.1159/000489089. Epub 2018 Jun 20.
9
Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.29例儿童结节性硬化症：临床与基因分析及面部血管纤维瘤对西罗莫司局部治疗的反应
Pediatr Dermatol. 2017 Sep;34(5):572-577. doi: 10.1111/pde.13204. Epub 2017 Aug 2.
10
A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.局部应用雷帕霉素和他克莫司联合治疗结节性硬化症相关的血管纤维瘤：一项不同疾病严重程度的 9 例日本结节性硬化症患者的初步研究
Br J Dermatol. 2011 Oct;165(4):912-6. doi: 10.1111/j.1365-2133.2011.10471.x.

引用本文的文献

1
Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis.雷帕霉素机制性靶点局部抑制剂治疗结节性硬化症患者面部血管纤维瘤的疗效与安全性：一项系统评价和网状Meta分析
Biomedicines. 2022 Mar 31;10(4):826. doi: 10.3390/biomedicines10040826.
2
Comparison of the In Vitro and Ex Vivo Permeation of Existing Topical Formulations Used in the Treatment of Facial Angiofibroma and Characterization of the Variations Observed.用于治疗面部血管纤维瘤的现有局部用制剂的体外和离体渗透比较及所观察到的变化特征
Pharmaceutics. 2020 Nov 7;12(11):1060. doi: 10.3390/pharmaceutics12111060.
3
Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial.
西罗莫司凝胶治疗结节性硬化症面部皮肤病变患者的安全性和有效性：一项长期、开放标签、扩展、非对照临床试验
Dermatol Ther (Heidelb). 2020 Aug;10(4):635-650. doi: 10.1007/s13555-020-00387-7. Epub 2020 May 8.
4
Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas.0.1%雷帕霉素亲水凝胶治疗面部血管纤维瘤的长期稳定性。
Eur J Hosp Pharm. 2020 Mar;27(e1):e48-e52. doi: 10.1136/ejhpharm-2018-001695. Epub 2018 Nov 10.
5
Long-Term Exposure and Safety of a Novel Topical Rapamycin Cream for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex: Results From a Single-Center, Open-Label Trial.一种新型外用雷帕霉素乳膏治疗结节性硬化症面部血管纤维瘤的长期暴露与安全性：一项单中心、开放标签试验的结果
Child Neurol Open. 2019 Apr 14;6:2329048X19835047. doi: 10.1177/2329048X19835047. eCollection 2019.
6
Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.局部他莫昔芬治疗结节性硬化症相关面血管纤维瘤的疗效和安全性：一项 TREATMENT 随机临床试验。
JAMA Dermatol. 2018 Jul 1;154(7):773-780. doi: 10.1001/jamadermatol.2018.0464.
7
Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.西罗莫司凝胶治疗与安慰剂治疗结节性硬化症患者面部血管纤维瘤：一项随机临床试验。
JAMA Dermatol. 2018 Jul 1;154(7):781-788. doi: 10.1001/jamadermatol.2018.1408.
8
The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis.神经嵴谱系作为结节性硬化症和淋巴管平滑肌瘤病疾病异质性的驱动因素。
Front Cell Dev Biol. 2014 Nov 25;2:69. doi: 10.3389/fcell.2014.00069. eCollection 2014.
9
Topical rapamycin as a treatment for fibrofolliculomas in Birt-Hogg-Dubé syndrome: a double-blind placebo-controlled randomized split-face trial.外用雷帕霉素治疗Birt-Hogg-Dubé综合征的纤维毛囊瘤：一项双盲安慰剂对照随机半脸试验。
PLoS One. 2014 Jun 9;9(6):e99071. doi: 10.1371/journal.pone.0099071. eCollection 2014.
10
Challenges in the management of a case of tuberous sclerosis.结节性硬化症一例的管理挑战
Ind Psychiatry J. 2012 Jul;21(2):148-51. doi: 10.4103/0972-6748.119635.